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Polymorphonuclear leucocytes (PMN) are known to produce superoxide and other oxygen derivatives upon 
activation as part of their microbicidal armory. Here we report that extracellular ascorbate is effectively 
oxidised by activated but not by resting human PMN in vitro. The oxidation of ascorbate is mainly caused 
by the superoxide that is generated by the activated ceils, as shown by its effective inhibition by superoxide 
dismutase. However, myeloperoxidase, which may generate hypochlorite, also contributes to a significant 
extent. Ascorbate reduces superoxide to peroxide, as indicated by measurements of the stoichiometry of 
ascorbate and oxygen consumption. These results support the notion that extracellular ascorbate may serve 
as an important physiological protecting agent against oxygen radical damage in inflammation. 
Ascorbate Superoxide Myeloperoxidase 
1. INTRODUCTION 
Activation of polymorphonuclear leucocytes 
(PMN) and other phagocytic cells is associated 
with an ‘oxygen burst’ [I ,2]. This is primarily due 
to the activation of a membranous NADPH ox- 
idase which catalyses reaction (1): 
202+ NADPH - 205- + NADP+ + H+ (1) 
The formed superoxide may disproportionate to 
dioxygen and hydrogen peroxide (reaction 2), 
either spontaneously or catalysed by superoxide 
dismutase (SOD): 
Oi- + Oi- + 2H+ - 02 + Hz02 (2) 
The formed hydrogen peroxide serves as a 
substrate for the myeloperoxidase reaction in the 
PMN, where chloride is converted to hypochlorite 
(reaction 3 13-51). 
Hz02 + Cl- ---+ ClO- + Hz0 (3) 
Alternatively, the hydrogen peroxide may be fur- 
ther reduced to the hydroxyl radical [l], or con- 
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sumed by the action of glutathione peroxidase or 
catalase. 
The physiological role of the oxygen burst and 
the associated produ~ion of toxic oxygen 
derivatives and hypochlorite in phagocytic ceils is 
to cause killing and destruction of foreign particles 
such as bacteria and viruses, and apparently of 
tumour cells as well [1,2]. However, the produc- 
tion of superoxide has also been suggested to con- 
tribute to the development and maintenance of 
some inflammatory states [6-91. Moreover, injec- 
tions of SOD have been found to suppress inflam- 
mation in three animal model systems [IO], and in 
humans [ 111. Also, hypochlorite has been im- 
plicated in inflammatory processes [12- 141. More 
generally, oxygen radicals have been proposed to 
be a major cause of cancer, heart disease and aging 
(review [15]). 
The extracellular defense against ‘oxygen 
radicals’ appears to depend on the rather low ac- 
tivities of SOD [ 161, and possibly on ascorbate [171 
and urate [15]. Here we have evaluated the effec- 
tivity of extracellular ascorbate in the protection 
against the production of oxygen radicals by ac- 
tivated PMN. The results are discussed in relation 
to the possible role of vitamin C in inflammation. 
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2. MATERIALS AND METHODS 
Human polymorphonuclear leucocytes (PMN) 
from peripheral blood were separated from other 
blood cells essentially as in [18]. Contaminating 
erythrocytes were haemolysed by a 20-30 s 
hypotonic treatment (pure water), and the cells 
were suspended in PBS medium (138 mM NaCI, 
2.7 mM KCl, 8.1 mM NatHPOs, 1.5 mM 
KH2P04 and 5 mM glucose) at 20 x lo6 cells/ml, 
and kept at room temperature. The trypan blue ex- 
clusion test indicated that ~98% of the cells were 
intact. 
Oxygen consumption was measured polaro- 
graphically with a Clark-type electrode in a closed 
thermostatted glass vessel with magnetic stirring. 
The final volume was 1.6 ml. 
Consumption of ascorbate was measured using 
two independent methods. In the first, oxidation 
of ascorbate was monitored spectrophotometrical- 
ly at 265 nm using an Aminco DW-2 spec- 
trophotometer. The thermostatted cuvette had a 
light path of 1 cm and the absorption scale was 
calibrated using known amounts of ascorbate. The 
second method was based on the reaction catalysed 
by ascorbate oxidase (EC 1.10.3.3), i.e., 
2 ascorbate + Ot - 2 dehydroascorbate + 
2 HzO. The measurement was carried out in the 
oxygraph. At various times, 12 pg/ml of ascorbate 
oxidase was added, which caused very rapid and 
stoicheiometric oxidation of the ascorbate that re- 
mained in the reaction mixture. This amount was 
determined on the basis of the extent of rapid 02 
consumption. 
All measurements were carried out at 37°C and 
pH 7.4. The reagents used were all commercial 
products of the highest purity available. 
3. RESULTS 
Spectrophotometric measurements revealed that 
ascorbate is consumed by activated but not by 
resting human PMN (fig.1). PMN may be ac- 
tivated by several different agents in vitro. We 
have tested the tumour promoter phorbol- 
myristate-acetate (PMA; fig. l), the lectin con- 
canavalin A, the calcium ionophore A-23187, and 
the bacterial chemotactic tripeptide formylmethio- 
nyl-leucyl-phenylalanine. In all cases, cell activa- 
tion initiated the consumption of ascorbate. The 
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Fig. 1. Oxidation of ascorbate by activated PMN. The 
ascorbate concentration was followed spectrophoto- 
metrically as described in section 2; 2 x IO6 cells were 
suspended in 3 ml PBS with 0.5 mM C&12. The initial 
concentration of ascorbate was 17 ,uM and that of PMA 
10 ng/ml. 
activation of 02 consumption and Oi- formation 
by these agents is typically preceded by a brief lag 
(fig.2). This lag is also seen in the consumption of 
ascorbate (fig.lA), but is lacking when the as- 
corbate is added to preactivated cells (fig.lB). 
These results were confirmed (not shown) using the 
ascorbate assay with ascorbate oxidase (see section 
2). 
To characterise the cause of ascorbate consump- 
tion, the effects of added SOD, azide and catalase 
were tested. SOD catalyses reaction 2, azide in- 
hibits myeloperoxidase (1191, reaction 3) and 
catalase accelerates breakdown of hydrogen 
peroxide. 
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Fig.2. Stimulation of net oxygen consumption by 
ascorbate; 2 x lo6 cells were suspended in 1.6 ml PBS + 
0.5 mM CaC12. The cells were activated by addition of 
16 ng/ml PMA. (a) Control; (b) 3 gg/ml of SOD; (c) 
25 pM ascorbate; (d) 50 pM ascorbate; (e) 250pM 
ascorbate. 
SOD effectively inhibited the consumption of 
ascorbate, whereas catalase and azide were much 
less effective (table 1, expt.1). This suggests that 
generated superoxide is the main species responsi- 
ble for ascorbate consumption, causing its oxida- 
tion to dehydroascorbate [ 171 according to reac- 
tion 4 (at pH 7.4): 
Ascorbate- + 2Oi- + 3H+ -+ 
dehydroascorbate + 2H202 (4) 
The small inhibitory effect of azide and catalase 
(table 1) suggests that also myeloperoxidase may 
be partially involved in the oxidation of ascorbate 
due to production of hypochlorite. On the other 
hand, hydroxyl radicals are apparently not in- 
volved in these conditions. If they were, an in- 
crease in the peroxide concentration by blockage 
of catalase and myeloperoxidase should enhance 
ascorbate oxidation, and in contrast, added 
catalase should be inhibitory. However, no dif- 
ference in the effects of azide and catalase was 
noted (table 1, expt 1). To further assess the possi- 
ble role of myeloperoxidase in ascorbate oxida- 
tion, we tested the effects of azide and catalase in 
the presence of SOD. When Oi- is efficiently 
dispropqtionated by SOD, it would be expected 
that a larger proportion of ascorbate breakdown 
would depend on myeloperoxidase. Indeed, in this 
situation the inhibition by catalase or azide reached 
about 80% (table 1, expts 2 and 3). 
Disproportionation of superoxide (reaction 2) 
regenerates half of the 02 that is reduced to 
superoxide in reaction 1. In such conditions the net 
oxygen consumption underestimates the true flux 
through NADPH oxidase. SOD did not 
significantly change the rate of net oxygen con- 
sumption by activated PMN (fig.2, cf. [20]). This 
may be expected since reaction 2 takes place spon- 
taneously, though with a much lower rate constant 
than when catalyzed by SOD. SOD hence causes a 
drastic decrease in the steady-state concentration 
of superoxide, which explains the inhibition of 
ascorbate oxidation (table 1, expt 1). When SOD is 
absent, ascorbate effectively reduces superoxide to 
peroxide (reaction 4) thus preventing the spon- 
taneous regeneration of dioxygen from superoxide 
by reaction 2. In agreement with this, ascorbate 
caused an approximately 2-fold stimulation of net 
02 consumption (fig.2). This is expected if reaction 
4 replaces reaction 2. With cell concentrations of 
about 2 x 106/ml only about 15-20pM of ascor- 
bate was required for full stimulation of net ox- 
ygen uptake (not shown). 
Fig.2 also shows that when limited amounts of 
ascorbate were present, the rate of oxygen con- 
sumption returned to control values after con- 
sumption of the added ascorbate. From the con- 
sumption of ascorbate and total 02, the ascor- 
bate/O2 ratio was found to be 0.48 and 0.65 in the 
presence and absence of azide (fig.3). The former 
value is in harmony with reactions 1 plus 4, i.e., in 
conditions where superoxide is the only oxidant of 
27 
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Table 1 
The effect of superoxide dismutase, azide and catalase on the rate of oxidation of 
ascorbate 
Additions Velocity 070 
@M/min) 
Expt 1 none 2.92 100 
azide, 0.1 mM 2.53 87 
catalase, 8 pg/ml 2.62 90 
SOD, 80 ng/ml 1.94 66 
SOD, 800 ng/ml 1.01 35 
SOD, 4 pg/ml 0.81 28 
Expt 2 
(SOD, 1.6 pg/ml) none 1.02 100 
azide, 0.1 mM 0.23 23 
Expt 3 
(SOD, 1.6 pg/ml) none 1.01 100 
catalase, 8 ag/ml 0.23 23 
Ascorbate oxidation by 2 x lo6 granulocytes was followed spectrophotometrically as 
in fig.1. The rate was determined from the linear part of the absorbance change. In 
experiment 1, the additions were made prior to the activator, which was 10 ng/ml 
PMA. In experiments 2 and 3 the SOD was added prior to the activator (10 ng/ml 
PMA), but azide and catalase were added when the ascorbate oxidation was linear. 
Both decreased the rate, which remained linear. The rate prior to addition of azide or 
catalase was used as control 
ascorbate. The 35% larger stoicheiometry in the 
absence of azide agrees with the notion that part of 
ascorbate may be oxidised in a myeloperoxidase- 
dependent fashion (e.g., by produced hypo- 
chlorite). 
Fig.3. Stoicheiometry between ascorbate oxidation and 
oxygen consumption in PMN. Basic conditions as in 
fig.2, but in the presence of 93 /IM ascorbate. At various 
times after activation with PMA, the remaining 
ascorbate was determined using the ascorbate oxidase 
assay (section 2). The total oxygen consumed from 
addition of PMA to addition of ascorbate oxidase was 
plotted against consumed ascorbate. Circles, no 
additions; squares, +O.l mM azide. The slopes were 
calculated by linear regression analysis (r = - 0.991 and 
- 0.998, respectively). 
28 
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4. DISCUSSION 
Our data show that extracellular ascorbate is ef- 
fectively oxidized by activated, but not by resting 
PMN, and that this occurs mainly as a reaction 
between ascorbate and superoxide, and to a lesser, 
but significant extent as ascorbate oxidation 
through myeloperoxidase action. The oxidation of 
ascorbate by superoxide is prominent at 
physiological extracellular concentrations of the 
vitamin (-50 PM in humans). The fact that oxida- 
tion of extracellular ascorbate by the activated 
PMN is stoicheiometric with consumption of 0~ 
shows that there is, in our conditions, no 
mechanism of sufficient kinetic capacity in these 
cells for re-reduction of extracellular dehydro- 
ascorbate or monodehydroascorbate to extracel- 
lular ascorbate. In agreement with this, addition of 
the former (not shown) did not simulate the effects 
of ascorbate described here. In [21,22] it was 
shown that PMN take up dehydroascorbate, 
reduce it to ascorbate, and concentrate it in this 
form. The lack of any effect of dehydroascorbate 
in our experiments may be due to the absence of a 
kinetically significant efflux of ascorbate from the 
cells. 
Authors in [23] reported a slight oxidation of in- 
tracellular ascorbate during phagocytosis of latex 
particles. In preliminary experiments we did not 
find any significant oxidation of intracellular 
ascorbate when the cells were stimulated by agents 
(such as PMA) which do not induce phagocytosis. 
This, together with the stoicheiometric onsump- 
tion of extracellular ascorbate with respect o con- 
sumed oxygen, supports the notion that NADPH 
oxidase functions vectorially with production of 
superoxide on the outside of the cell membrane. 
This would imply that during phagocytosis 
superoxide is produced into the primary 
phagosome rather than into the cytoplasm. Yet, a 
considerable fraction of superoxide is probably 
released extracellularly as well during phagocytosis 
(see [24]). 
The concentration of superoxide dismutase in 
human extracellular fluids is found to be low when 
care is taken to prevent leakage of the enzyme 
from cells. In serum a special high molecular mass 
isoenzyme accounts for most of the superoxide 
dismutase activity [ 161. At normal extracellular 
ascorbate concentrations the vitamin would be ex- 
petted to react more effectively with superoxide 
than extracellular SOD [16]. On the basis of our 
results it seems likely, therefore, that one of the 
functions of extracellular vitamin C is to minimize 
tissue damage caused by expulsion of superoxide 
and hypochlorite from activated PMN during an 
inflammatory response. Since ascorbate reduces 
Oi- to hydrogen peroxide, the latter important 
substrate for the myeloperoxidase reaction would 
still be produced. The combination of reactions 1 
and 4 implies, in fact, that ascorbate can be a co- 
reductant with NADPH in the reduction of 02 to 
peroxide by the activated cells. The proposed an- 
tioxidant function of urate [15] may complement 
rather than exclude that suggested here for ascor- 
bate, since the former is ineffective against 
superoxide (unpublished), and all toxic oxygen 
metabolites are produced via superoxide in 
phagocytic cells [ 11. 
Enhanced rates of oxidation of ascorbate may, 
according to our data, be expected in connection 
with inflammation due to activation of a large 
number of PMN. This could result in a decrease of 
the steady-state concentration of the reduced 
vitamin, at least locally. Enhanced oxidation of 
ascorbate would be expected to favour depletion of 
the vitamin because dehydroascorbate is much less 
stable than ascorbate, and is effectively degraded 
and excreted [25]. A site of inflammation could 
therefore also constitute a drain of vitamin C from 
the whole organism. Leucocyte and plasma levels 
of ascorbate are significantly decreased in many 
different disorders [25], for example, the common 
cold [26,27], rheumatoid arthritis [28,29], and 
myocardial failure [30]. The mechanism proposed 
here could contribute to such changes. A decrease 
in ascorbate concentration may, in turn, result in 
diminished protection against toxic oxygen 
metabolites derived from superoxide, but also 
other ascorbate-dependent reactions, such as the 
biosynthesis of collagen [31], may tend to proceed 
less efficiently. 
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